Recent developments in fast disintegrating tablets have brought convenience in dosing to pediatric and elderly patients who have trouble in swallowing tablets. The objective of the present study was to prepare the fast disintegrating tablet of salbutamol sulphate for respiratory disorders for pediatrics. As precision of dosing and patient's compliance become important prerequisites for a long-term treatment, there is a need to develop a formulation for this drug which overcomes problems such as difficulty in swallowing, inconvenience in administration while travelling, and patient’s acceptability. Hence, the present investigation were undertaken with a view to develop a fast disintegrating tablet of salbutamol sulphate which offers a new range of products having desired characteristics and intended benefits. Superdisintegrants such as sodium starch glycolate was optimized. Different binders were optimized along with optimized superdisintegrant concentration. The tablets were prepared by direct compression technique. The tablets were evaluated for hardness, friability, weight variation, wetting time, disintegration time, and uniformity of content. Optimized formulation was evaluated by in vitro dissolution test, drug-excipient compatibility, and accelerated stability study. It was concluded that fast disintegrating tablets of salbutamol sulphate were formulated successfully with desired characteristics which disintegrated rapidly; provided rapid onset of action; and enhanced the patient convenience and compliance. 1. Introduction Despite tremendous innovations in drug delivery, the oral route remains the preferred route for administration of therapeutic agents because of accurate dosage, low cost therapy, self medication, noninvasive method, and ease of administration leading to high level of patient compliance [1]. The most popular dosage forms are conventional tablets and hard gelatin capsules. One important drawback of such dosage forms is “dysphagia” or difficulty in swallowing for many patients; almost 50% of the population is affected by such problem. Hence, patients do not comply with prescription, which results in high incidence of noncompliance and ineffective therapy [2].Recently, fast disintegrating drug delivery systems have started gaining popularity and acceptance as new drug delivery systems, because they are easy to administer and lead to better patient compliance [3]. In some cases such as motion sickness, sudden episodes of allergic attacks or coughing, and unavailability of water, swallowing conventional tablets may be difficult.
References
[1]
R. Pahwa, M. Piplani, P. C. Sharma, D. Kaushik, and S. Nanda, “Orally disintegrating tablets—friendly to pediatrics and geriatrics,” Archives of Applied Science Research, vol. 2, no. 2, pp. 35–48, 2010.
[2]
S. Divate, K. Kavitha, and G. N. Sockan, “Fast disintegrating tablets—an emerging trend,” International Journal of Pharmaceutical Sciences Review and Research, vol. 6, no. 2, pp. 18–22, 2011.
[3]
R. Panigrahi and S. A. Behera, “Review on fast dissolving tablets,” Webmed Central Quality and Patient, vol. 1, no. 9, pp. 1–17, 2010.
[4]
M. Slowson and S. Slowson, “What to do when patients cannot swallow their medications,” Pharma Times, vol. 51, pp. 90–96, 1985.
[5]
S. Corveleyn and J. P. Remon, “Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug,” International Journal of Pharmaceutics, vol. 152, no. 2, pp. 215–225, 1997.
[6]
A. K. Nayak and K. Manna, “Current developments in orally disintegrating tablet technology,” Journal of Pharmaceutical Education and Research, vol. 2, no. 1, pp. 21–34, 2011.
[7]
S. A. Sreenivas, P. M. Dandagi, A. P. Gadad et al., “Orodispersible tablet: new-fanged drug delivery system—a review,” Indian Journal of Pharmaceutical Education and Research, vol. 39, no. 4, pp. 177–181, 2005.
[8]
D. Bhowmik, B. Chiranjib, K. Pankaj, and M. R. Chandira, “Fast dissolving tablet: an overview,” Journal of Chemical and Pharmaceutical Research, vol. 1, no. 1, pp. 163–177, 2009.
[9]
B. G. Prajapati and N. Ratnakar, “A review on recent patents on fast dissolving drug delivery system,” International Journal of PharmTech Research, vol. 1, no. 3, pp. 790–798, 2009.
[10]
M. Swamivelmanickam, R. Manavalan, and K. Valliappan, “Mouth dissolving tablets: an overview,” International Journal of Pharmaceutical Sciences and Research, vol. 1, no. 12, pp. 43–55, 2010.
[11]
K. D. Tripathi, Essential of Medical Pharmacology, pp. 216–217, Jaypee Brothers Medical, New Delhi, India, 6th edition, 2008.
[12]
S. B. Jadhav, D. R. Kaudewar, G. S. Kaminwar, A. B. Jadhav, R. V. Kshirsagar, and D. M. Sakarkar, “Formulation and evaluation of dispersible tablets of diltiazem hydrochloride,” International Journal of PharmTech Research, vol. 3, no. 3, pp. 1314–1321, 2011.
[13]
V. Metker, A. Kumar, N. Pathak, K. Padhee, and S. Sahoo, “Formulation and evaluation of orodispersible tablets of lornoxicam,” International Journal of Drug Development and Research, vol. 3, no. 1, pp. 281–285, 2011.
[14]
A. Arya, S. Sharma, J. Kumar, A. Chandra, and P. Jaiswal, “Formulation and evaluation of mouth dissolving tablets of ranitidine HCL,” International Journal of Pharm Tech Research, vol. 2, no. 2, pp. 1574–1577, 2010.
[15]
R. B. Parmar, A. H. Baria, H. M. Tank, and S. D. Faldu, “Formulation and evaluation of domperidone fast dissolving tablets,” International Journal of PharmTech Research, vol. 1, no. 3, pp. 483–487, 2009.
[16]
B. Senthilnathan and A. Rupenagunta, “Formulation development and evaluation of venlafaxine hydrochloride orodispersible tablets,” International Journal of Pharmaceutical Sciences and Research, vol. 2, no. 4, pp. 913–921, 2011.
[17]
P. B. Anjankumar, M. Nazmuddin, U. Kulkarni, and R. C. Hariprasanna, “Formulation and evaluation of lornoxicam fast dissolving tablet,” International Research Journal of Pharmacy, vol. 2, no. 4, pp. 130–133, 2011.
[18]
N. C. Mohire and A. V. Yadav, “Novel approach to formulate β-cyclodextrin complexed mouth dissolving tablet of metronidazole and its in-vitro evaluation,” Journal of Pharmacy Research, vol. 3, no. 3, pp. 662–667, 2010.
[19]
ICH Harmonised Tripartite Guideline. Cover Note for Revision of Q1A(R) Stability Testing of New Drug Substances and Products.Q1A (R2): pp. 9.